Advertisement
UK markets closed
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • HANG SENG

    17,284.54
    +83.27 (+0.48%)
     
  • CRUDE OIL

    82.51
    -0.30 (-0.36%)
     
  • GOLD FUTURES

    2,342.10
    +3.70 (+0.16%)
     
  • DOW

    37,939.37
    -521.55 (-1.36%)
     
  • Bitcoin GBP

    51,265.51
    -521.82 (-1.01%)
     
  • CMC Crypto 200

    1,386.82
    +4.25 (+0.31%)
     
  • NASDAQ Composite

    15,494.08
    -218.67 (-1.39%)
     
  • UK FTSE All Share

    4,387.94
    +13.88 (+0.32%)
     

Is There Now An Opportunity In Taubman Centers, Inc. (NYSE:TCO)?

Taubman Centers, Inc. (NYSE:TCO), which is in the reits business, and is based in United States, led the NYSE gainers with a relatively large price hike in the past couple of weeks. As a well-established company, which tends to be well-covered by analysts, you could assume any recent changes in the company’s outlook is already priced into the stock. However, what if the stock is still a bargain? Today I will analyse the most recent data on Taubman Centers’s outlook and valuation to see if the opportunity still exists.

See our latest analysis for Taubman Centers

Is Taubman Centers still cheap?

Great news for investors – Taubman Centers is still trading at a fairly cheap price. According to my valuation, the intrinsic value for the stock is $69.07, but it is currently trading at US$53.25 on the share market, meaning that there is still an opportunity to buy now. Taubman Centers’s share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. If you believe the share price should eventually reach its true value, a low beta could suggest it is unlikely to rapidly do so anytime soon, and once it’s there, it may be hard to fall back down into an attractive buying range.

What kind of growth will Taubman Centers generate?

NYSE:TCO Past and Future Earnings, February 17th 2020
NYSE:TCO Past and Future Earnings, February 17th 2020

Investors looking for growth in their portfolio may want to consider the prospects of a company before buying its shares. Although value investors would argue that it’s the intrinsic value relative to the price that matter the most, a more compelling investment thesis would be high growth potential at a cheap price. Though in the case of Taubman Centers, it is expected to deliver a highly negative earnings growth in the next few years, which doesn’t help build up its investment thesis. It appears that risk of future uncertainty is high, at least in the near term.

What this means for you:

Are you a shareholder? Although TCO is currently undervalued, the negative outlook does bring on some uncertainty, which equates to higher risk. Consider whether you want to increase your portfolio exposure to TCO, or whether diversifying into another stock may be a better move for your total risk and return.

ADVERTISEMENT

Are you a potential investor? If you’ve been keeping an eye on TCO for a while, but hesitant on making the leap, I recommend you research further into the stock. Given its current undervaluation, now is a great time to make a decision. But keep in mind the risks that come with negative growth prospects in the future.

Price is just the tip of the iceberg. Dig deeper into what truly matters – the fundamentals – before you make a decision on Taubman Centers. You can find everything you need to know about Taubman Centers in the latest infographic research report. If you are no longer interested in Taubman Centers, you can use our free platform to see my list of over 50 other stocks with a high growth potential.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.